News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Kenneth M. Verburg, for the SUCCESS VI Study Group (Reprinted from Th

Articles by Kenneth M. Verburg, for the SUCCESS VI Study Group (Reprinted from Th

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

ByAndrew Whelton,John G. Fort,Joseph A. Puma,Diane Normandin,Alfonso E. Bello,Kenneth M. Verburg, for the SUCCESS VI Study Group (Reprinted from Th

October 1st 2002

Latest Updated Articles

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients
Published: October 1st 2002 | Updated:

Trending on AJMC

Prior Authorization Ranked Top Barrier to Health Care Access After Cost

Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM

Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024

FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.